The Angeles Clinic and Research Institute

What The Angeles Clinic and Research Institute does

The Angeles Clinic and Research Institute is a private, for-profit oncology center operating two adjacent locations on the west side of Los Angeles — West Los Angeles and Santa Monica (1919 Santa Monica Boulevard, Fourth Floor). Founded in 1999, the practice delivers multidisciplinary cancer care through 11 specialty centers covering brain, breast and women's cancers, gastrointestinal, head and neck, hematology, lung and thoracic, melanoma and skin, prostate and men's cancers, personalized therapy, a Phase 1 clinical trial unit, and a medical imaging center. The clinic serves individual cancer patients primarily through physician referrals, self-referrals, and second opinion consultations, with an established international reputation attracting inbound referrals.

The clinic's clinical capabilities span immunotherapy (PD-1/PD-L1 checkpoint inhibitors, Ipilimumab, and the Sipuleucel-T/PROVENGE therapeutic cancer vaccine), targeted therapy (BRAF, MEK, Hedgehog, and NRAS inhibitors), and an advanced radiation platform including IMRT, IGRT, stereotactic radiosurgery and radiotherapy, 3D/4D conformal therapy, and brachytherapy. Its research profile is the core differentiator: The Angeles Clinic was the first US site to offer the Ipilimumab/Nivolumab combination via a Phase III collaboration with Memorial Sloan Kettering Cancer Center, the first to have Lambrolizumab (MK-3475) designated an FDA breakthrough therapy, and played a major role in the YERVOY FDA approval for melanoma. Active Phase 1 trials with pharmaceutical partners sustain a research-as-service revenue stream, and Dr. Hamid (Director of Melanoma Program) anchors the immunotherapy research line, with Dr. Cathie Chung (recruited from City of Hope in 2009) leading breast cancer novel-agent work.

Revenue is generated through professional services — direct patient care (medical oncology, hematology, radiation, surgical consultations), clinical trial participation, and second opinion consultations — with a quote-based, insurance-covered pricing model. Patient acquisition relies on physician referrals, clinical publications and ASCO presentations, medical conferences, a monthly patient newsletter, and a website-hosted patient education library, with no retail or e-commerce distribution. Charitable giving flows through the affiliated nonprofit The Angeles Clinic Foundation.

Name

The Angeles Clinic and Research Institute

Legal name

The Angeles Clinic & Research Institute

Website

https://theangelesclinic.org

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

The Angeles Clinic and Research Institute is a private oncology center operating two Los Angeles locations (West Los Angeles and Santa Monica), delivering multidisciplinary cancer treatment, immunotherapy, targeted therapy, radiation, and Phase 1 clinical trials across 11 specialty centers to cancer patients regionally and internationally.

Ownership category

akta.pro rank

Product category

Specialty Oncology Services

NAICS

Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Urologic Oncology (HLAKAOAB), Neuro-Oncology (HLAKAFAH), Gastrointestinal Oncology (HLAKAFAK)

Keywords

• Oncology treatment services
• Cancer clinical trials
• Radiation oncology
• Immunotherapy services
• Personalized cancer therapy

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Services Revenue: Revenue generated from providing cancer treatment services including immunotherapy, targeted therapies, radiation therapy, and surgical consultations.
2. Clinical Trial Services: Revenue from participation in clinical trials in collaboration with pharmaceutical partners, including Phase I clinical trials.
3. Second Opinion Consultations: Revenue from specialized consultation services for patients seeking expert second opinions on cancer diagnosis and treatment.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

The Angeles Clinic and Research Institute provides specialized multidisciplinary cancer care across organ-specific oncology programs (brain, breast, gastrointestinal, head and neck, hematologic, lung, melanoma, prostate) and runs a Phase 1 Clinic plus broader Clinical Trial Program offering investigational and newly approved therapies. It delivers immunotherapy, targeted therapy, and advanced radiation oncology services supported by an in-house Medical Imaging Center, personalized therapy planning, and second opinion consultations. The institute primarily serves individual cancer patients in the Los Angeles area.

Product overview

The Angeles Clinic and Research Institute is a cancer care and research facility offering a multi-specialty approach to cancer treatment across 11 distinct specialty centers. The organization provides comprehensive cancer care services including medical oncology, hematology, radiation therapy, immunotherapy, and targeted therapies. Key specialty centers include Brain Cancer & Neuro-Oncology, Breast Cancer & Women's Cancers, Gastrointestinal Cancer, Head & Neck Cancer, Hematology & Oncology, Lung & Thoracic Cancer, Melanoma & Skin Cancer, Phase 1 Clinic, Personalized Therapy, Prostate Cancer & Men's Cancers, and a Medical Imaging Center. The institute offers advanced treatment modalities including FDA-approved immunotherapies (PROVENGE, PD1/PD-L1 inhibitors, Ipilimumab), targeted therapies (BRAF inhibitors, MEK inhibitors), various radiation therapy techniques (IMRT, IGRT, stereotactic radiosurgery), and conducts Phase 1 clinical trials. The organization also provides patient education resources, second opinion consultations, and maintains active clinical research programs in partnership with pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Brain Cancer & Neuro-Oncology Specialty clinical program providing diagnosis, treatment, and ongoing care for patients with brain tumors and other central nervous system cancers, delivered at the institute's Los Angeles-area clinics.
• Breast Cancer & Women's Cancers Specialty clinical program for breast and other women's cancers, providing medical oncology, surgical coordination, radiation therapy, and access to clinical trials for affected patients.
• Gastrointestinal Cancer Specialty clinical program for gastrointestinal cancers (including colorectal, pancreatic, gastric, and hepatobiliary cancers), offering systemic therapy, clinical trial enrollment, and multidisciplinary care planning.
• Head & Neck Cancer Specialty clinical program for head and neck cancers, providing medical oncology, coordination with surgical and radiation oncology, and clinical trial access for patients with these malignancies.
• Hematology & Oncology Specialty clinical program for hematologic malignancies and benign blood disorders, providing diagnosis, systemic therapy, and clinical trial options for leukemia, lymphoma, myeloma, and related conditions.
• Lung & Thoracic Cancer Specialty clinical program for lung and thoracic cancers, providing systemic therapy, targeted therapy, immunotherapy, and clinical trial enrollment for patients with thoracic malignancies.
• Melanoma & Skin Cancer Specialty clinical program for melanoma and other skin cancers, providing systemic therapy, immunotherapy, targeted therapy, and clinical trial options for affected patients.
• Phase 1 Clinic Dedicated clinical unit administering Phase 1 oncology clinical trials, providing patients with access to first-in-human and early-phase investigational therapies not yet broadly available.
• Personalized Therapy Service for developing individualized treatment plans that integrate molecular profiling, targeted therapy selection, and tailored supportive care for cancer patients.
• Prostate Cancer & Men's Cancers Specialty clinical program for prostate and other men's cancers, providing hormonal therapy, chemotherapy, targeted therapy, and clinical trial enrollment for affected patients.
• Medical Imaging Center On-site imaging service providing diagnostic imaging for cancer diagnosis, staging, treatment planning, and treatment response assessment for institute patients.
• Clinical Trial Program Broader research program offering patients enrollment in oncology clinical trials beyond Phase 1, including Phase 2 and Phase 3 studies of investigational and newly approved therapies.
• Second Opinion Consultation Consultative service for patients seeking an independent review of an existing cancer diagnosis or treatment plan, delivered by institute subspecialists across the relevant disease program.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 1 January 2013Collaboration on Ipilimumab and Nivolumab combination therapy clinical trials. First site in United States with ability to offer this combination therapy through major phase III collaborative effort. Joint data presentation at ASCO and publication in New England Journal of Medicine.
• Pharmaceutical PartnerscoreStrategic or Co-development Partner · 1 January 2013Collaboration with pharmaceutical companies instrumental in bringing targeted therapies and immunotherapies to patients. Participation in Phase I clinical trials and FDA breakthrough therapy programs.
• City of Hope Cancer CenterminorOthersSource institution for Dr. Cathie Chung who joined the Breast Cancer Program bringing expertise in novel biologic therapeutics and targeted agents.

Scale indicators2 records

Expansion highlights5 records

Broad incumbents

• City of Hope Comprehensive Cancer Center: Large NCI-designated comprehensive cancer center in the greater Los Angeles area with a broad portfolio of oncology specialty programs, clinical trials, and precision medicine services. Directly comparable to Angeles Clinic as a regional academic-grade competitor and an actual talent source (Dr. Chung came from City of Hope).
• UCLA Health Jonsson Comprehensive Cancer Center: NCI-designated comprehensive cancer center based in West Los Angeles, offering multi-disciplinary oncology specialty programs, Phase I trials, immunotherapy, and radiation therapy. Overlaps heavily with Angeles Clinic's specialty centers and target patient base in the same metro.
• Stanford Cancer Institute: NCI-designated comprehensive cancer center affiliated with Stanford University offering multi-specialty oncology care, immunotherapy, and early-phase clinical trials. Comparable to Angeles Clinic in model and historically the training ground of Dr. Chung before her move to Angeles Clinic.
• USC Norris Comprehensive Cancer Center: NCI-designated comprehensive cancer center in Los Angeles offering multi-specialty oncology care, Phase I trials, and translational research. A direct institutional competitor for specialty oncology referrals and clinical trial enrollment.
• Memorial Sloan Kettering Cancer Center: National oncology leader and Angeles Clinic's named research collaborator on the landmark Ipilimumab/Nivolumab combination trial. Comparable in its multi-specialty oncology, immunotherapy, and clinical trial model, but operates at vastly greater national scale.
• Cedars-Sinai Medical Center (Cancer Program): Major Los Angeles academic medical center with a multidisciplinary cancer program covering medical, surgical, and radiation oncology plus clinical trials. Competes for the same affluent Westside patient population as Angeles Clinic.

Regional players

• Hoag Family Cancer Institute: Community-based, multi-specialty oncology program in Orange County/greater Southern California offering medical oncology, radiation, and clinical trials. Comparable private-practice-style specialty cancer model competing for affluent Southern California patients.
• Providence Saint John's Health Center (Cancer Institute): West Los Angeles hospital-based cancer program offering multidisciplinary oncology services, clinical trials, and infusion therapy. Directly competes in the same geographic catchment for community oncology referrals.

Direct peers

• Sarah Cannon Research Institute: Specialized oncology clinical trial network conducting Phase I and Phase II oncology studies across multiple US sites. Comparable to Angeles Clinic's Phase I Clinic as a focused early-phase oncology trial operator with pharma partnerships.
• Los Angeles Cancer Network: Southern California community oncology group practice offering multi-site medical oncology, infusion, and clinical trial services. Closely comparable as a private, multi-location specialty oncology practice competing for similar patient segments in the LA metro.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Angeles Clinic and Research Institute